Posted 19 July, 2021
TScan Therapeutics, Inc. IPO completed
IPO completed detected for ticker Nasdaq:TCRX in a 424B4 filed on 19 July, 2021.
This is our initial public offering and no public market currently exists for our shares of common stock.
Don't know how to trade IPO completion? Read Initial Public Offerings.
Overview of TScan Therapeutics, Inc.
Health Care/Life Sciences • Biotechnology
TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions, to enable the development of efficacious TCR-Ts. The company was founded by Christoph H. Westphal, Stephen Elledge, Lea Hachigian, and Tomasz Kula in 2018 and is headquartered in Boston, MA.Market Cap
$310M
View Company Details
$310M
Interested in special situations?
Join Tickerverse
- customize event filters
- create watchlists, bookmarks
- get email notifications for the latest special situations
- browse and analyze public companies, executives and SEC filings
Tickerverse is a great way to find investment opportunities in corporate actions.
By signing up you agree to our Terms of Service and Privacy Policy.